| Program | Target | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Anticipated milestones in 2024 |
|---|---|---|---|---|---|---|---|
| Eblasakimab | IL-13Rα1 | Atopic dermatitis |
|
||||
| COPD |
|
||||||
| Farudodstat | DHODH | Alopecia areata |
|
Eblasakimab
Eblasakimab is a novel, fully human, monoclonal IgG4 antibody that binds specifically to the Interleukin (IL)-13 receptor, preventing signaling of IL-4 and IL-13 through the Type 2 receptor. Eblasakimab is currently being developed as a treatment for moderate-to-severe atopic
dermatitis (AD).
Farudodstat
Farudodstat is an orally active, potent inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), that suppresses T cell proliferation and secretion of Interferon Gamma (IFNγ) by blocking de novo production of pyrimidines required for DNA replication.
